secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001193125-24-250665
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista raises $60M in public offering and private placement to fund sebetralstat
--------------------------------------------------------------------------------

- Public offering of 5.5M shares at $10.00 per share for gross proceeds of $55M; net ~$51.3M.
- Concurrent private placement of 500K shares to DRI Healthcare Acquisitions LP for $5M gross; net ~$4.7M.
- Proceeds will fund continued clinical development of sebetralstat and pre-commercialization activities.
- Offering and private placement expected to close November 5, 2024; closings not contingent on each other.
- Jefferies, BofA Securities, TD Cowen, and Stifel serving as joint book-running managers and placement agents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524250665/0001193125-24-250665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524250665/d907269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-250665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer